Evidence map›Paper›PMID 29067461›Full record

ArticleMolecular medicine reports2017

Mori Folium water extract alleviates articular cartilage damages and inflammatory responses in monosodium iodoacetate‑induced osteoarthritis rats.

Jin-Woo Jeong, Hye Hyeon Lee, Jongsik Kim, Eun-Ok Choi, Hyun Hwang-Bo, Hong Jae Kim, Min Young Kim, Kyu Im Ahn, Gi-Young Kim, Ki Won Lee and 6 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Therapeutic effects of combining curcumin and swimming in osteoarthritis using a rat model.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Aqueous Extract ofFrontiers in pharmacology · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Jin-Woo JeongOpen Laboratory for Muscular and Skeletal Disease and Anti‑Aging Research Center, Dongeui University, Busan 614‑714, Republic of Korea.
Hye Hyeon LeeOpen Laboratory for Muscular and Skeletal Disease and Anti‑Aging Research Center, Dongeui University, Busan 614‑714, Republic of Korea.
Jongsik KimDepartment of Anatomy, Kosin University College of Medicine, Busan 602‑702, Republic of Korea.
Eun-Ok ChoiOpen Laboratory for Muscular and Skeletal Disease and Anti‑Aging Research Center, Dongeui University, Busan 614‑714, Republic of Korea.
Hyun Hwang-BoOpen Laboratory for Muscular and Skeletal Disease and Anti‑Aging Research Center, Dongeui University, Busan 614‑714, Republic of Korea.
Hong Jae KimOpen Laboratory for Muscular and Skeletal Disease and Anti‑Aging Research Center, Dongeui University, Busan 614‑714, Republic of Korea.
Min Young KimOpen Laboratory for Muscular and Skeletal Disease and Anti‑Aging Research Center, Dongeui University, Busan 614‑714, Republic of Korea.
Kyu Im AhnOpen Laboratory for Muscular and Skeletal Disease and Anti‑Aging Research Center, Dongeui University, Busan 614‑714, Republic of Korea.
Gi-Young KimLaboratory of Immunobiology, Department of Marine Life Sciences, Jeju National University, Jeju 690‑756, Republic of Korea.
Ki Won LeeResearch Institute, Bio‑Port Korea, Inc., Marine Bio‑industry Development Center, Busan 619‑912, Republic of Korea.
Ki Young KimResearch Institute, Bio‑Port Korea, Inc., Marine Bio‑industry Development Center, Busan 619‑912, Republic of Korea.
Sung Goo KimResearch Institute, Bio‑Port Korea, Inc., Marine Bio‑industry Development Center, Busan 619‑912, Republic of Korea.
Su Hyun HongDepartment of Biochemistry, Dongeui University College of Korean Medicine, Busan 614‑052, Republic of Korea.
Cheol ParkDepartment of Molecular Biology, College of Natural Sciences and Human Ecology, Dongeui University, Busan 614‑714, Republic of Korea.
Hee-Jae ChaDepartment of Parasitology and Genetics, Kosin University College of Medicine, Busan 602‑702, Republic of Korea.
Yung Hyun ChoiOpen Laboratory for Muscular and Skeletal Disease and Anti‑Aging Research Center, Dongeui University, Busan 614‑714, Republic of Korea.
Dong-Eui University · KRMarine Biodiversity Institute of Korea · KRKosin University · KRJeju National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mori folium, the leaf of Morus alba L. (Moraceae), has been widely used in traditional medicine for the treatment of various diseases. It has been recently reported that Mori folium possesses potential chondroprotective effects in interleukin (IL)‑1β‑stimulated human chondrocytes; however, its protective and therapeutic potential against osteoarthritis (OA) in an animal model remains unclear. In this study, as part of an ongoing screening program to evaluate the anti‑osteoarthritic potential of Mori folium, the protective effects of a water extract of Mori folium (MF) on cartilage degradation and inflammatory responses in a monosodium iodoacetate (MIA)‑induced OA rat model were evaluated. The results demonstrated that administration of MF had a tendency to attenuate the damage to articular cartilage induced by MIA, as determined by knee joint swelling and the histological grade of OA. The elevated levels of matrix metalloproteinases‑13 and two bio‑markers for the diagnosis and progression of OA, such as the cartilage oligomeric matrix protein and C‑telopeptide of type II collagen, were markedly ameliorated by MF administration in MIA‑induced OA rats. In addition, MF significantly suppressed the production of pro‑inflammatory cytokines, including IL‑1β, IL‑6 and tumor necrosis factor‑α. MF also effectively inhibited the expression of inducible nitric oxide (NO) synthase and cyclooxygenase‑2, thus inhibiting the release of NO and prostaglandin E2. Although further work is required to fully understand the critical role and clinical usefulness, these findings indicate that MF may be a potential therapeutic option for the treatment of OA.

Indexed as

AnimalsCartilage, ArticularCelecoxibCytokinesDinoprostoneDisease Models, AnimalDown-RegulationInterleukin-1betaInterleukin-6IodoacetatesKnee JointMaleMatrix Metalloproteinase 13MorusNitric OxideOsteoarthritisCelecoxibCytokinesDinoprostoneInterleukin-1betaInterleukin-6IodoacetatesMatrix Metalloproteinase 13Nitric OxidePlant ExtractsTumor Necrosis Factor-alpha

Identifiers

PMID29067461
PMCPMC5646961
OpenAlexW2736584597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.